Previous 10 | Next 10 |
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101 Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (...
Quarterly Loss Was Less Than We Estimated. PDS Biotech reported 2Q22 loss of $5.8 million or $(0.20) per share, beating our estimated loss of $8.8 million or $(0.34) per share. The differences were largely due to R&D expense of $3.7 million compared with our estimate of $5.3 million, as we...
PDS Biotechnology Corporation (PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022, 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer M...
PDS Biotechnology press release ( NASDAQ: PDSB ): Q2 GAAP EPS of -$0.20 beats by $0.08 . Cash balance as of June 30, 2022 was approximately $53M. “We made tremendous progress this quarter with our lead candidate, PDS0101, across all four ongoing Phase 2 clin...
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology meeting Promising pre-clinical data on universal flu vaccine program presented at American So...
ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...
PDS Biotechnology ( NASDAQ: PDSB ) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s ( MRK ) anti-PD-1 therapy, Keytruda be continued without changes...
FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune &...
FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune &...
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary V...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...